Figure 1 from Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models

Bevacizumab provides a survival benefit in a subset of MDA-MB-231 tumors but not MCF7 tumors. A, Illustrative overview of study design (created with BioRender.com). Mouse viewpoint from left side shows only the left flank tumor; right flank tumor not shown. B, Survival curves for control (Ctrl) and bevacizumab (Bev)-treated groups in MCF7 tumor-bearing mice (top, nmice = 4 Ctrl; nmice = 4 Bev) and MDA-MB-231 tumor-bearing mice (bottom, nmice = 8 Ctrl; nmice = 11 Bev). C, Estimated average tumor growth per group for the control group and the bevacizumab-treated group of MDA-MB-231 mice (ntumors = 14 Ctrl; ntumors = 20 Bev), illustrating the durable response obtained in the subset of the treated group denoted as responders (Bev-R) compared with nonresponders (Bev-NR) based on their tumor growth rates (see Supplementary Data). Shaded areas show 95% pointwise confidence bounds for the average. The largest tumor volume recorded in the study was less than 3,200 mm3 in accordance with our ethical limits; data beyond this volume is an extrapolation of our linear model to illustrate the trajectory of growth in Ctrl and Bev-NR tumors. Weeks denoted in B and C are from the time of enrollment.